Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pan-PIM kinase inhibitor GDC-0570

An orally available small molecule pan-inhibitor of the PIM serine/threonine kinase family, with potential antineoplastic activity. Upon oral administration, pan-PIM kinase inhibitor GDC-0570 binds to and prevents the activation of the three PIM family kinases, PIM1, PIM2 and PIM3. This prevents the activation of PIM-mediated signaling pathways and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	pan-PIM kinase inhibitor NB004
Code name:	GDC 0570 GDC-0570 GDC0570 NB 004 NB-004 NB004

pan-PIM kinase inhibitor GDC-0570

Search NCI's Drug Dictionary